KR950031106A - 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물 - Google Patents

종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물 Download PDF

Info

Publication number
KR950031106A
KR950031106A KR1019950012503A KR19950012503A KR950031106A KR 950031106 A KR950031106 A KR 950031106A KR 1019950012503 A KR1019950012503 A KR 1019950012503A KR 19950012503 A KR19950012503 A KR 19950012503A KR 950031106 A KR950031106 A KR 950031106A
Authority
KR
South Korea
Prior art keywords
component
necrosis
pharmaceutical composition
inflammatory diseases
tumors
Prior art date
Application number
KR1019950012503A
Other languages
English (en)
Other versions
KR100386492B1 (ko
Inventor
보쓸렛 클라우스
체흐 외르크
호프만 디터
Original Assignee
슈타인, 라우페
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 라우페, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 라우페
Publication of KR950031106A publication Critical patent/KR950031106A/ko
Application granted granted Critical
Publication of KR100386492B1 publication Critical patent/KR100386492B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 종양 또는 염증 조직에서 괴사를 유발시키는 물질(성분I)과 기타 무독성 물질("선구 약물, 성분II)과의 배합물에 관한 것이다. 괴사 과정에 의해 유리된 효소는 무독성 “선구약물”을 절단하여 독성 “약물”이 되게 하고, 이는 거대한 종양 세포를 죽게 하고/하거나 염증을 경감시킨다.

Description

종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 종양 및 염증질환에서 괴사를 유발시키는 성분I로서의 하나 이상의 활성 화합물 및 유발된 괴사에 의해 활성화되는 성분 II로서의 하나 이상의 활성 화합물을 함유하는, 세포 증식 억제 또는 면역 조절 치료법에서 동시에(성분 I과 II의 혼합물은 동시 사용의 경우에 포함된다), 별도로 또는 일시적으로 단계적으로 사용하기 위한 배합 제제로서 약제학적 조성물.
  2. 제1항에 있어서, 성분 I이 발명의 상세한 설명의 a) 내지 b)에서 기술된 화합물 중 하나 이상을 함유하는 약제학적 조성물.
  3. 제1항에 있어서, 성분 I이 증식 내피, 바람직하게 특히 VEGF/VEGF 수용체 복합체에 대해 선택적인 하나 이상의 모노클로날 항체 또는 수용체 리간드를 함유하는 약제학적 조성물.
  4. 제1항에 있어서, 성분 I이 증식 내피 세포에 생기는 하수유도증(apoptosis)-매개 항원, 바람직하게는 αvβ3인테그린에 대한 하나 이상의 모노클로날 항체 또는 리간드 또는 길항질을 함유하는 약제학적 조성물.
  5. 제1항에 있어서, 성분 I이 하나 이상의 세포 독성 면역 배합체를 함유하는 약제학적 조성물.
  6. 제1항에 있어서, 성분 I이 하나 이상의 리간드 독소를 함유하는 약제학적 조성물.
  7. 제1항에 있어서, 종양 세포 대사-억제 물질 또는 내피 세포 대사-억제 물질을 함유하는 약제학적 조성물.
  8. 제1항에 있어서, 성분 II로서 EP 제0 540 859 A1호 및 EP 제0 595 133 A2호에 기술된 선구 약물 중 하나를, 바람직하게는 tjs약물 N-(4-β-글루쿠로닐-3-니트로벤질옥시카보닐)독소루빈신을 사용하는 약제학적 조성물.
  9. 종양 및 염증 질환에서 괴사를 유발시키는 하나 이상의 활성 화합물(성분 I)과 유발된 괴사에 의해 활성화되는 하나 이상의 활성 화합물(성분 II)의 배합물의, 종did는 염증성 질환 치료용 약물의 제조에 사용하기 위한 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950012503A 1994-05-20 1995-05-19 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물 KR100386492B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4417865.4 1994-05-20
DEP44171865.4 1994-05-20
DE4417865A DE4417865A1 (de) 1994-05-20 1994-05-20 Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Publications (2)

Publication Number Publication Date
KR950031106A true KR950031106A (ko) 1995-12-18
KR100386492B1 KR100386492B1 (ko) 2003-08-14

Family

ID=6518684

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950012503A KR100386492B1 (ko) 1994-05-20 1995-05-19 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물

Country Status (14)

Country Link
US (1) US5710134A (ko)
EP (1) EP0696456B1 (ko)
JP (1) JP4576005B2 (ko)
KR (1) KR100386492B1 (ko)
AT (1) ATE199645T1 (ko)
AU (1) AU2015195A (ko)
CA (1) CA2149818C (ko)
DE (2) DE4417865A1 (ko)
DK (1) DK0696456T3 (ko)
ES (1) ES2154693T3 (ko)
GR (1) GR3035593T3 (ko)
NZ (1) NZ272150A (ko)
PT (1) PT696456E (ko)
ZA (1) ZA954099B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU2004202605B2 (en) 1998-07-13 2007-10-25 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
CA2369263A1 (en) * 1999-04-09 2000-10-19 Jessie Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
ES2312478T3 (es) * 2000-09-07 2009-03-01 Bayer Schering Pharma Aktiengesellschaft Receptor del dominio edb de fibronectina (ii).
AU2002316305A1 (en) * 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases
ES2299590T3 (es) * 2001-08-10 2008-06-01 Imclone Systems, Inc. Uso medico de celulas madre que expresan vegfr-1.ng vegfr-1.
NZ584715A (en) 2002-07-15 2011-12-22 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
EP1722762A2 (en) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
JP4636020B2 (ja) * 2004-05-26 2011-02-23 株式会社ニコン 波長変換光学系、レーザ光源、露光装置、マスク検査装置、及び高分子結晶の加工装置
SI1819358T1 (sl) 2004-11-18 2014-10-30 Imclone Llc Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
CA2669138A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
KR20100102110A (ko) 2007-11-09 2010-09-20 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) * 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU1768692A (en) * 1991-03-27 1992-11-02 Lankenau Medical Research Center Method of administering drugs through modification of epithelial tight junctions
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PT696456E (pt) 2001-07-31
GR3035593T3 (en) 2001-06-29
EP0696456A2 (de) 1996-02-14
ATE199645T1 (de) 2001-03-15
AU2015195A (en) 1995-11-30
NZ272150A (en) 1997-04-24
DE4417865A1 (de) 1995-11-23
KR100386492B1 (ko) 2003-08-14
CA2149818A1 (en) 1995-11-21
US5710134A (en) 1998-01-20
DK0696456T3 (da) 2001-06-25
JPH07316074A (ja) 1995-12-05
EP0696456A3 (de) 1998-10-28
ES2154693T3 (es) 2001-04-16
DE59509088D1 (de) 2001-04-19
CA2149818C (en) 2010-03-23
JP4576005B2 (ja) 2010-11-04
EP0696456B1 (de) 2001-03-14
ZA954099B (en) 1996-01-19

Similar Documents

Publication Publication Date Title
KR950031106A (ko) 종양 및 염증성 질환의 선택적 치료를 위한 괴사-유발물질과 괴사에 의해 활성화되는 물질과의 배합물
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE192921T1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
NO20064395L (no) Anvendelse av buprenorfin i fremstilling av et medikament
DE69232263D1 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
AR040603A1 (es) El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
ATE392902T1 (de) Nigella sativa als medizinische behandlung
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
TR199800717T2 (xx) Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
BR0113552A (pt) Lipossomas que encapsulam fármacos anticancerìgenos e uso dos mesmos no tratamento de tumores malignos
KR970703783A (ko) 종양 치료를 위한 조성물 및 방법(Compositions and Methods for the Treatment of Tumors)
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
SE8302580L (sv) Substituerade iminoderivat av dihydrobensopyran och dihydrobensotiopyran och forfarande for deras framstellning
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
TR199901237T2 (xx) Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�.
IT1271688B (it) Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110421

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee